semlerresearch

Part of US based
Semler Group of Companies,
in business since 1946

Sitemap

YOU ARE HERE: Home News & Events Latest News
Latest News
Semler Research Center inspected and approved by EMA

The inspection focused on the bio-equivalence study conducted for the product. EMA inspectors visited the facility to review study documents generated at Clinical facility and Bioanalytical facility, Bangalore. The study was approved by the regulatory.

 
Semler Research Center inspected and approved by ANVISA

The inspection focused on the bio-equivalence study conducted for the product. ANVISA inspectors visited the facility to review study documents generated at the Clinical facility, Salem and the Bioanalytical facility, Bangalore. The study was approved by the regulatory.

 
Semler Research Center successfully completes 4th WHO inspection

The inspection focused on the bio-equivalence studies conducted at Semler Research center. The inspection covered all the sections of the GCP and GLP, including the WHO guidance for organizations performing in vivo bioequivalence studies. Inspector visited the facility to review the study documents generated at Clinical facilities & Bio analytical facility at Bangalore. The inspection was completed successfully.

Readmore

 
Fresh Round of Investment and Growth Plans for Semler Research Center

Agoura Hills, California, United States, Tuesday, October 01, 2013 -- (Business Wire India)

Semler Research Centre Pvt. Ltd. (SRC), a leading Contract Research Organization based in Bengaluru, India entered into an agreement with Excel Dwellings (EDI) for development of products. EDI will fund intially USD 5 Million which will be utilised for product development opportunities. EDI will work closely with SRC for development of products in regulated markets through an exclusive manufacturing and distribution partner.

Readmore…

 
Semler Research Center US Appoints Dr Nuggehally Srinivas as the President of Specialty Pharma

Agoura Hills, United States

Semler Research Center US (SRC US) has announced its formation of a new business unit within Arnold A Semler Inc, which also owns SRC India, and the appointment of Dr Nuggehally Srinivas as the President. Dr Srinivas will leverage his expertise to build and develop a business strategy for the seamless execution of a Specialty Pharma vertical which will be designed to assist academics, biotechs, start-ups and VCs in evaluating investment decisions on product selection inclusive of clinical and regulatory strategy. Specialty Pharma will also focus on risk: reward sharing models with collaborating partners within the scope of the chosen therapeutic areas with differentiated products in areas such as oncology, pain/inflammation, and neurosciences among others.

Read more….

 
  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  3 
  •  4 
  •  Next 
  •  End 
  • »


Page 1 of 4

Quick Contact

INDIA Tel: +91 80 4262 7200

US Tel:+1 818 760 1000

info@semlerresearch.com